Cargando…

Current Staging Procedures in Urinary Bladder Cancer

Currently computed tomography (CT) represents the most widely used standard imaging modality in muscle-invasive urinary bladder cancer. Visualization of local tumor or depth of invasion as well as lymph node staging, however, is often impaired. Magnetic resonance imaging (MRI) with diffusion-weighte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maurer, Tobias, Horn, Thomas, Heck, Matthias, Gschwend, Jürgen E., Eiber, Matthias, Beer, Ambros J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665464/ https://www.ncbi.nlm.nih.gov/pubmed/26824925 http://dx.doi.org/10.3390/diagnostics3030315

Ejemplares similares

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
por: Thalgott, Mark, et al.
Publicado: (2014)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer
por: Wieder, Hinrich, et al.
Publicado: (2017)

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
por: Dewes, Sabrina, et al.
Publicado: (2016)

A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients
por: Peeken, Jan C., et al.
Publicado: (2020)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?
por: Knipper, Sophie, et al.
Publicado: (2021)

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
por: Begum, Nusrat J., et al.
Publicado: (2019)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Diagnostic significance of MRI versus CT using identical PET data in patients with recurrent differentiated thyroid cancer: A PET/MRI study
por: Westphal, Korbinian, et al.
Publicado: (2023)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

Double-strand breaks in lymphocyte DNA of humans exposed to [(18)F]fluorodeoxyglucose and the static magnetic field in PET/MRI
por: Brix, Gunnar, et al.
Publicado: (2020)

Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients
por: Thalgott, Mark, et al.
Publicado: (2015)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?
por: Maurer, Tobias, et al.
Publicado: (2017)

Multiparametric 18F–FDG PET/MR follow-up in a patient with autoimmune pancreatitis
por: Rauscher, Isabel, et al.
Publicado: (2017)

Current and Emerging Bladder Cancer Urinary Biomarkers
por: Parker, Justin, et al.
Publicado: (2011)

KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
por: Lunger, Lukas, et al.
Publicado: (2020)

Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer
por: Loeffelbein, Denys J, et al.
Publicado: (2014)

A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer
por: Vogel, Marco M. E., et al.
Publicado: (2021)

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Development and external validation of a multivariable [(68)Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer
por: Muehlematter, Urs J., et al.
Publicado: (2023)

Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study
por: Schmid, Sebastian C., et al.
Publicado: (2015)

Impact of (68)Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer
por: Schiller, K., et al.
Publicado: (2018)

A population-based method to determine the time-integrated activity in molecular radiotherapy
por: Hardiansyah, Deni, et al.
Publicado: (2021)

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
por: Wang, Hui, et al.
Publicado: (2021)

Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer
por: Vogel, Marco M. E., et al.
Publicado: (2021)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Evaluation of Pre-operative Biopsy, Surgical Procedures and Oncologic Outcomes in Upper Tract Urothelial Carcinoma (UTUC)
por: Koll, Florestan J., et al.
Publicado: (2021)

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
por: Habl, Gregor, et al.
Publicado: (2017)

Urinary markers for bladder cancer
por: Smith, Zachary L., et al.
Publicado: (2013)

Visualization of stress fractures of the foot using PET-MRI: a feasibility study
por: Crönlein, Moritz, et al.
Publicado: (2015)

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers
por: Matuszczak, Milena, et al.
Publicado: (2022)

The added value of PSMA PET/MR radiomics for prostate cancer staging
por: Solari, Esteban Lucas, et al.
Publicado: (2021)

Pediatric urolithiasis: the current surgical management
por: Straub, Michael, et al.
Publicado: (2010)

Pre-test (68)Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model
por: Kraft, Pia, et al.
Publicado: (2020)

Role of multiparametric magnetic resonance imaging in the diagnosis and staging of urinary bladder cancer
por: Shalaby, Essam A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sscpe90e4uuprsdqnb6ecvsok6